Infusion or co-infusion of brain natriuretic peptide and/or adrenomedullin in human heart failure  by Lainchbury, J.G. et al.
M 
O 
N 
13 
Y 
P 
O 
S 
T 
E 
R 
156A ABSTRACTS- P~ster JACC Fehntary. 1998 
~ Plasma Brain Netrluretlc Peptlde Levels Increase 
in Proportion to the Extant of Right Ventrleular 
Dysfunction In Pulmonary Hypertension 
N. Nagoya, T, Nlshlklml, Y, Oknno, M, Uematsu, T, Batch, S, Kyotanl, 
S, Kurlbayashl, K, Keng~wa, National Cardiovascular Center, Osaka, dapnn 
B~ckgrOund: Plasma BNP Is known to Increase In proporllon to the degree 
of left vontficular (LV) overload. However, whether brain natrluretlc peptlde 
(BNP) secretion is also regulated in the presence of right ventrlcular (RV) 
ovedoed remains unknown, This study sou0hf to Investigate the Influence 
of RV hemodynemlcs and function on the secretion of BNP in patients with 
Isolated RV overload, 
Methane: Plasma BNP and atrial nntrluratlo peptldo (ANP) levels in the 
pulmonary artery wora measured In 44 patients with RV overload', RV volume 
overload (RVVO) due to atrial aeptal defect (n ,, 18) end RV pressure overload 
(RVPO) due to pdm~Iry or thremboemboll¢ pulmonary hypertension (n .  20), 
Right hear1 catheterization wee performed tn ell patients, RV and LV ejection 
fraetlon, myocardial mass, and volume of the 4 chambers were determined 
,,sing electron beam computed tomogmphy, 
Re.~utta: Though both plasma BNP and ANP were slgnlflcently elevated 
In RV ovodoad compared with control sublects, plasma BNP and BNPIANP 
ratio were significantly higher In RVPO th~n In RVVO (BNP', 294:1 72 vs, 
48 ;I 14 pg/ml, BNP/ANP: 1,6 :t 0,2 vs, 0,8 ~ 0,9, p ~ 005, respectively), 
Plasm~ BNP positively correlated with mann pulmonary arterial pressure (r 
0,73), total pulmonary resistance (r ~ 0,Tg), mean fight atrial pressure (r 
0,Tg), RV end.diastolic pros~,lro ( r .  0,70), and RV myocardial mass (r - 
0,71); negatively correlated with cardiac output (r = 0,33) and RV ejection 
fraction ( r .  0,71), Plasma BNP significantly decreased from 315 t 120 to 
144 • 54 pg/ml by long term vasodllator therapy (total pulmonary resistance 
decreased from 23 ~ 4 to 15 ~:~ 3 Wood units), 
Conclusions: Plasma BNP levels increase in proportion to the extent of 
RV dysfunction In pulmonary hypedonslen. 
~ Therapeutic and Limitation of  Human Effects 
Atrial Natriumtlc Peptlde in Patients With 
Congestive Heart Failure 
H, Watanabe ~ , M, Kakthana, S, Ohtsuka, Y, Suglshlta. ~KINU Medical 
A.qsoctMton Hospital, MIt~ukaldo, Japan: University of Tsukut~l, Tsuku~l, 
Japan 
Backgro~md: Alpha human atrial natrlumtlc poptide (ANP) Is available as a 
therapeutic agent for congestive heart failure. Continuous adminiMratton of 
ANP has L'oen reported to induce the attenuation of hemodynamic effects in 
patients with congostLve head failure due to dounregulatlon of ANP receptors. 
This study was designed to elucidate the relationship between levels of 
endogenous ANP and therapeutic effects of exogenous ANP. 
Methods: Fourteen patients with congestive head failure were divided tote 
two groups on the basis of baseline level of endogenous ANP (pg/ml) (high 
group: c250, n = 7; low group: ..250, n = 7). After baseline measurements 
were obtained, dose titration was stared by infusing ANP at a rate of 0.05 
I=glkglmin, After achieving the desired hemodynamlc response (30% reduc- 
tion of putmonary adory pressure), the infusion rate of ANP was maintained 
for 24 hours. Measurements of hemodynamic parameters and blood sam- 
piing were pedormed serially at the baseline, 6, 12, 18, and 24 hours after 
the infusion, 
Results: At the baseline, moan pulmonary artery pressure (PA, mmHg), 
mean pulmonary capillary wedge pressure (PCWP, mmHg), and plasma 
cGMP level were comparable in the two groups, At 6 hours after the infusion 
of ANP, PA and PCWP were significantly decreased (high group: PA, 47 .~: 
6 to 33 ± 5; PCWP, 23 *. 6 to 15 :~ 4; low group, PA: 45 ± 8 to 32 ± 6; 
PCWP: 24 ± 8 to 16 ~ 5), and plasma cGMP (pmol/ml) was signiticantty 
increased (high group, 8 i 3 to 39 ~: 11; low group, 3 ~: 2 to 44 :~ 13). 
However, at 12 hours, in the high group, PA (39 ~- 11) and PCWP (21 t: 5) 
were significantly elevated (p -: 0.05 vs at 6 hours) and plasma cGMP (14 
:~- 6) was significantly decreased (p < 0.05 vs at 6 hours). In contrast, in the 
low group, the effects on PA (29 :~: 5), PCWP (17 ~ 4) and plasma cGMP 
(39 t: 11) were maintained at 12 hours. 
Conclusion: ANP is a potentially useful therapeutic agent for congestive 
heart failure in patients with low level of endogenous ANP, But the effects 
may be attenuated in patients with high level of endogenous ANP during 
continuous administration of ANP. 
~ Infusion or  Co- infus ion of  Brain Natrluretic 
Peptlde And/or Adrenomedul l in in Human Heart 
Failure 
J.G. Lainchbury, AM. Richards, M.G. Nicholls, E.A. Espiner, T.G. Yandte. 
Christchurch Hospital, Christchurch, New Zealand 
In random order, placebo controlled, studies we gave 4 I~our (hi infusions of 
Brain Natrluretlc Peptlde (B) (3.0 pmol/kg/mln), Adrenomedultln (A) (2.65 end 
5,3 pmol/kg/min; 2 h each) or both combined (C) to 6 males with congestive 
heart failure (CHF, left ventficutar ejection fractions <35%). Blood pressure 
(BP) fell with B, A and C (peak falls: systolic 10, 20 end 23 mmHg end 
diastolic 8, 17, 19 mmHg respectively, p -~ 0,01 for all), Heart rote Increased 
with A and G (peak increase 13 bpm for both, p .~ 0,01), Plasma B increased 
with B end C (peak Increase 00pmol/L for both, p < 0,01), A was Increased 
by A end C (peak Increase 60 pmot/L for both, p < 0,01). Atdal netfiumttc 
pepUde, eplnephfine and cortisol were unchanged, Noreplnephrlna (NE) wee 
Increased by B, A end C (peek rise 650, 1103, end 1403 pmol4 ret=pectlvely, 
I,e, by 31.-66%, p ~- 0,01), Renln was unchanged by B but Increased by A 
nnd C (peek rise 320 and 2g0%, p < 0,01) whilst aldostomne was elmtlar 
on each day, Sodium excretion Increased with B and C (peak Increase t2,8 
end 10,9 mmoll4 hre respectively, p .: 0,05 for both), A, B end C Infusions 
causecl significant decreases In BP (the greatest with A end C). Increases 
in heart rate, NE and rentn o~urmd durlilg A and C Infusions, but only NE 
mac with B, The expected aldostemna response to meier tnc~see in renln 
was blocked by A, B (but not A) had e significant natfiurobo effect which 
was presented with C despite n marked fall in BP, Co.augmentatton of Brain 
Natrlurelle Peptldo and Admnomedullln systems has unique hemodynamic 
effects In human CHF, 
~ enhan©oment of Renal 11-/3-Hydroxysterold 
Oehydrogenen A©tlvlty In Chronic  Heart Failure 
andEseentlel Hypertension 'freatecl With 
ACE-inhibit ion 
D, Dupmz, M, De Buyzoro, M, Paellnck, J,.M, Kautman, R. Rubens, 
D, Clement, Uatwrslty Hospital. Gent, Belgium 
Background: ACE-Inhibition Is a currant treatment for born chron¢; imact fail- 
ure (CHF) and essential hypertension (EHT), Steroid metabolism is known 
to be Intedemd with by chronic ACE.Inhibition and may lead to the so called 
steroid escape phenomenon, We tested the hypothesis whether chronic ACE- 
inhibition differently influences codisone/codisot excretion due to activation 
of renal 11,# hydmxystorold ehydregenase, 
Methods: Thirteen patients (71 4:6 year~) with chronic heart failure (CHF, 
NYHA class ff, ejection fraction 32 ± 13%) under a stable therapy with 
captopril tOO mg/d and furesomldo 40 mg/d wore examined together with 7 
patients (61 ± 6 years) with essential hypedension (EHT) treated with cap- 
topfi150 mg/d for at least 3 months. 24 Hours urine (U) was collected for the 
determination of cedisone (1) and cortisol (2) metabolites and their ratio using 
HPLC chromatography as well as blood sampling for the renin-angiotenstn- 
aldosterene system in supine position. 
Results: 
Plasm~ CHF EHT 
Ronln(.U/ml) 95r t 1479 120 t 117 P- O001 
Angtotonstnll(pglml) 34.2 ~ 277 21.1 * 114 P OO1 
Atdostorono (ng/dl) 189 ~ 13.4 11 2 t 9 1 P 0 05 
U.conisono (1) flag'S4 h) 64 ~ 36 39 t 25 P • 0.01 
U-cortisot(2) (1~g!24 hi 33 t: 21 30 : 19 N5 
(1)!(2) ratio 2.10 t 0,76 1.51 t 116 P - 0.05 
Conclusions: In essential hypertension and chronic head failure under 
chronic ACE-inhibition there is a steroid escape phenomenon which is sig- 
ntflcanUy greater in the head failure process. The higher cortisone/cortisol 
ratio in chmnlc heart failure under ACE-inhibition suggests a morn enhanced 
renal 11-/¢ hydrexystemid ehydregenase activity in chronic heart failure. 
~ Anglotens ln  Converting Enzyme Delet ion 
Polymorphism Does Not Increase the Risk of 
Heart Fai lure 
D.M. McNamare, M,K. Trest, A.D. Palmer, M Rudy, R.J. Alvarez, Jr., 
WD. Rosenblum. G.A, MacGowan, S. Murali, A,M. Feldman, University of 
Pittsburgh Medical Center, Pittsburgh. Pennsylvania. USA 
Backgreund: The role of the deletion allele of the angiotensin converting 
enzyme (ACE "D") as a risk factor for the development congestive heart 
failure remains controversial. In this case control study we sought to evaluate 
the hypothesis that the deletion allele would be increased in prevalence in a 
heart lailure population, when compared to age matched controls. 
Methods: r)NA was isc, latsd from whole blood and ACE genotyping per- 
formed on a series of 212 patients (P) with congestive heart failure referred 
to the Head Failure service at the University of Pittsburgh (M/F 160/52, age = 
55.3 ~ 7 11.4). These were compared to a series of 124 controls (C) without 
any history of heart failure or coronary disease (M/F 74150 age = 54.7 ± 
10.2) 
Results: The frequency of homozygotes for the insertion allele (11), het- 
erozygotes (ID), or homozygotes for the deletion allele (DD), did not differ 
between patients and controls as is displayed by the table below. 
